Sunho Biologics says independent committee finds investigator qualified, independent amid trading suspension

• Sunho Biologics issued a supplemental clarification on its appointed investigator as trading remains suspended.
• The independent investigation committee assessed the investigator as independent from the group, directors, major shareholders, connected persons, auditors.
• An eight-person forensic team was assigned, led by a senior partner with more than 18 years’ audit, forensic experience.
• The committee cited experience with Stock Exchange-listed probes, resources aligned to resumption guidance timelines.
• Share trading has been halted since April 1, 2026, pending publication of the 2025 annual results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290776), on August 19, 2026, and is solely responsible for the information contained therein.